## IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

OMOWALE A. SHABAZZ	)	
	)	
Plaintiff,	)	
	)	
<b>V</b> .	)	<b>CIVIL CASE NO. 3:13-CV-00091</b>
	)	
DERRICK SCHOFIELD, et al.	)	
	)	
Defendants	)	

# AFFIDAVIT OF DR. KENNETH WILLIAMS, MEDICAL DIRECTOR FOR THE TENNESSEE DEPARTMENT OF CORRECTION

I, Dr. Kenneth Williams, being duly sworn, make the following sworn statements:

- 1. I am employed as the Medical Director for the Tennessee Department of Correction (TDOC) and its correctional facilities. I am a Medical Doctor and I hold a Ph.D. in Microbiology. I have experience in both inpatient and outpatient care, and was in private practice, until I assumed my current position with the Department of Correction. While in private practice, I held hospital privileges at Centennial, Baptist, and Summit Hospitals in Nashville, Tennessee.
- 2. My current responsibilities include, but are not limited to, managing the Department's contract with its medical services vendor and its deliverables, reviewing credentials of potential providers; reviewing and monitoring "sentinel events", which are encounters requiring infirmary admission, emergency room visits, and/or hospital admissions; monitoring processes and programs to ensure chronic health maintenance; and establishing processes and programs to improve acute health issues with the Department's inmate population.
- 3. I am currently a member of a national panel on Hepatitis C treatment, sponsored by Gilead Sciences, Inc. As a member of that panel, I attend regular meetings related to the

direction of Hepatitis C treatment in a correctional setting, as well as in the community. I also regularly attend conferences with other medical professionals from other state correctional systems to discuss issues related to healthcare delivery and treatment of diseases in the correctional setting and its challenges.

### Mr. Shabazz's Case

- 4. I have reviewed inmate Omowale Shabazz's (aka Fred Dean), TDOC #244104, medical record in order to advise this Court as to Mr. Shabazz's current health status and to respond to the allegations he makes concerning his alleged medical condition.
- 5. Mr. Shabazz is enrolled in a chronic care review program and his status is monitored regularly by a dedicated infectious disease monitor as well as the facility medical staff.
- 6. Mr. Shabazz has been diagnosed with the Hepatitis C virus, Genotype 1.
- 7. The primary early indicator of whether treatment of Hepatitis C is warranted, is the regular and consistent monitoring of liver enzyme levels. Specifically, the SGOT/AST and SGPT/ALT levels. SGOT/AST is an enzyme that is normally present in liver and heart cells and is released into the blood when the liver or heart is damaged. SGPT/ALT is most commonly found in the liver and is used as measurable indicator of liver function and liver health.
- 8. Both of these tests indicate specific liver enzyme production and/or lack thereof. All inmates in the custody of the Tennessee Department of Correction that have been diagnosed with Hepatitis C are monitored for increased liver enzyme levels on a regular basis. They are also assessed by physical exam to evaluate for any symptoms at regularly scheduled intervals.
- 9. In reviewing Mr. Shabazz's medical record, it appears as though he has had lab work conducted at least 13 times since January of 2013. (True and exact copies of the lab reports are attached hereto, and consist of 19 pages).

- 10. Mr. Shabazz's liver enzyme levels were most recently tested on March 25, 2015. At that time, his SGOT/AST level was at 25, with a reference range of 15-40 and SGPT/ALT = 23 with a reference range of 7-45. The reference range is the median of all persons providing a specimen to that particular laboratory, which includes people without Hepatitis C. The levels indicate that Mr. Shabazz's liver is functioning as it should, and in the same range as persons that do not have Hepatitis C. (See Lab Reports, P. 2). Furthermore, Mr. Shabazz's liver enzyme levels are indicative that his liver is not in active cirrhosis.
- 11. In accordance with Mr. Shabazz's liver enzyme levels and his medical file as a whole, the Hepatitis C virus has yet to warrant the treatment which Mr. Shabazz seeks. In fact, his current levels do not warrant treatment at all, but do require continued monitoring. Because Mr. Shabazz is a member of the chronic care review program, he will continue to be monitored on a continual basis, along with all other inmates who have been diagnosed with Hepatitis C.
- 12. His Hepatitis C is stable and he is not in any way in an acute phase. The Department's general policy is to monitor enzyme levels at least every 3 months for all inmates diagnosed with Hepatitis C. This policy is consistent with generally accepted medical practices, regardless of whether the patient is incarcerated or is a free world patient.
- 13. Mr. Shabazz's Hepatitis C is in a stable state and is not progressing. In some cases only time will tell if this is true in Mr. Shabazz's case the Hepatitis C disease never progresses to a point which requires treatment and while diagnosed with Hepatitis C, one's liver may always function normally.
- 14. In addition to Mr. Shabazz's stable liver enzyme level, in December 2014, the Doctor's notes in Mr. Shabazz's medical file indicate that during his physical examination, he showed no indication of pain and did not communicate any pain to the examining physician. Furthermore, there has been no indication of any jaundice in Mr. Shabazz's eye exams. Jaundice is yellowing

of the white of a patient's eyes, which is direct physical evidence of less than optimum liver function. If Mr. Shabazz had presented with yellowing of the eyes, further tests would be conducted to reevaluate the status of Mr. Shabazz's Hepatitis C.

- 15. Mr. Shabazz's health or safety is not presently at risk, due to his Hepatitis C. The type of Hepatitis which Mr. Shabazz has, Genotype I, is not such that it will cause immediate and unforeseen health risks. With regular testing of a patient's enzyme levels, increased levels can be monitored to determine if treatment is necessary, as other unrelated factors can cause increased liver enzymes, independent of a Hepatitis C diagnosis.
- 16. Should Mr. Shabazz's enzyme levels change to such a degree that treatment is warranted, he will be provided with appropriate treatment.

#### Department's Approach to Hepatitis C Treatment

- 17. The Department's Hepatitis C Treatment Guidelines were developed for application at all of the Department's correctional institutions. The guidelines were developed with input from experts in the community practicing infectious disease and gastroenterology (A true and exact copy of the Guidelines are attached hereto).
- 18. Generally, the responsible course of medical treatment action for Hepatitis C is to monitor enzyme levels and track the patient until the patient shows the initial signs of possible damage, i.e. consistently increased enzyme levels. Specific to Genotype 1, treatment can proceed if an inmate is not scheduled for release within 15 months. This time frame is required in order to ensure that the round of treatment can occur and be completed. It is especially important that a patient not be started on a Hepatitis C regimen which they cannot complete. Not completing the treatment can be harmful and is not without side effects which can be a serious detriment to a patient's health. In addition, beginning treatment, and not completing treatment can harm a patient's chances at a cure in the future.

19. Assuming that the SGOT/AST and SGPT/ALT levels have been consistently at or above the top end of the reference range, we look at the certain indicators, generally, clotting and coagulation factors and viral load. We then apply the SAFE algorithm to determine the level of cirrhosis (i.e. liver scarring) and the pathway of appropriate treatment.

Kenneth Williams, M.D., Ph.D.

**Medical Director** 

Tennessee Department of Correction

STATE OF TENNESSEE COUNTY OF DAVIDSON

On the day of \_\_\_\_\_\_, 2015, appeared personally before me, Kenneth Williams, M.D., Ph.D., known to be of lawful age and did sign and swear under penalties of law, the aforesaid Affidavit in my presence.

)

Sworn to and subscribed before me this GR day of May, 2015.

[Notary Seat] STATE OF OF TENNESSEE NOTARY PUBLIC SON COUNTING

Marcia E. Campay Notary Public

My commission expires: 07-03-2017



2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN TUCKER, CORTEZ		FRED	SEX M	ACCESSION NO. 201503895842	CONTROL NO. 655181
FACILITY NO. NWCX	оов 09/17/1959	ACCO PRIS	UNT NO. 6407940	DATE COLLECTED 03/25/2015 06:50	DATE RESULTED 03/27/2015 01:57
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID		ATE ID 44104		

Abnorma1s	Summary				W.
NEUTROPHILS	33.7	LYMPHOCYTE	58.2	RED BLOOD CELLS	4.36
HEMOGLOBIN	12.0	HEMATOCRIT	40.4	MCHC	29.6
MPV	11.9	4 kg 8		- F 3.	

Test Description	Result	Abnormal	Flag	Reference Ran	ge Units	Prev Lab Res
ASTING				col: 03/25/	2015	Status: F
CBC	201		1 1	150-400	TH/CUMM	211
PLATELET COUNT	201 	na segre et en 1915.	17/19/06/06	4.0-10:0	TH/CU MM	Comment of the second second of the second
WHITE BLOOD COUNT	7.41 A. A.			1.56-8.10	x10-3/uL	2.01
ABSOLUTE NEUTROPHIL CT	2.43	N-72-175-7-24-64-1	1 72 200	39-81	XIU-3/UL	31.2
NEUTROPHIES		33.7		Control of the second s	769 (C)	SECURIO DE PARA PORTO
LYMPHOCYTE	namen viji seletin samen kultura (1965).	58.2	H	14-51	%	60.2 6.4
MONOCYTES	6.7			<b>.0-13</b> .3	% 1 Fig. 14	Charles Seen so c
EOSINOPHIL	1.1	Brich (daylar Assalla Naida	-	0-8	<b>%</b> ere madazatas	1.2
BASOPHILS	0.4			0-2	<b>%</b>	1.0
RED BLOOD CELLS	(MO	4.36	LL	4.41-5.51	M/CU MM	4.64
HEMOGEOBIN	er and	/H 12.0	EL	135-175	G/DL	12.6
HEMATOCRIT		40.4	LL	41-53	%	41.5
MCV	92.8		1. 1	80-105	FEE FU	89.4
MCH	27.5		1 1	27-33	PG	27.1
MCHC	Littler at the E	29.6	"[	31,-37	G/DL	30.3
RDW	13.5		1	11.5-14.5	%	14.1
Mpv. 36-38-40-6-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	ALPERTAL APPLICATION	11.9	H	7.4-10.4	FLL &	12.2
CMP				col: 03/25/	2015	Status: F
ALBUMIN	4.1			3.5-5.5	G/DL	4.0
ALK PHOS	\$.121			53-128	U/L	139
TOTAL BILIRUBIN	0.4	Distributari, e Makember i Husi		0.2-1.2	MG/DL	0.7
BUN	12 is			7-18	MG/DL	11
Color and Carlot and all supplies and arrangement and account of the	9.5	A SECTION OF THE PERSON OF THE		8.4-10.7	MG/DL	98
CALCIUM	Total State	THE APPLICATION OF STREET	in a	98-107	MEQ/L	103
CHLORIDE	0.89	<b>对</b> 特别为2000年	nikesiina)	0.7-1.3	MG/DL	0.94
CREATININE, SERUM	Control of the Contro	HERCHEV KEINE FOR		60-300	mL/MIN	89
GER (NON-AER AMER)		NATURAL STREET		60-300	mL/MIN	107
GFR (AFR AMER)	114	. Leronz D. Vielhe	orn MD		may riser	
80 MI DI	Director	: Lorenz P. Kieinc	)  I , MD	Thomas	Mr.	∩0 . Pg: 1,
Printed: 03/27/2015 04:43	Con 200091 Document	<i>tinued on Nex</i> 1 563 Filed 05/0	<i>page</i> 06/15	Thomas Family Me Page 6 of 28	Concluded D. #	Mag Sho
3333 3.23 37		8	<del>-</del>	× × ×	Thysic	lian ()



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN TUCKER, CORTEZ		AMĘ , <b>FRED</b>	SEX M	ACCESSION NO. 201503895842	CONTROL NO. 655181
FACILITY NO. NWCX	оов 09/17/1959	ACCO PRIS	UNT NO. 6407940	DATE COLLECTED 03/25/2015 06:50	DATE RESULTED 03/27/2015 01:57
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID	•	ATE ID 44104		

Test Description	Result	Abnormal	Flag	Reference Rar	ige Units	Prev Lab Res
GLUCOSE	7,6			70-105	MG/DL	70
POTASSIUM	4.4			3.5-5.1	MEQ/L	4.7
- TOTAL PROTEIN	7.2			6.0-8.3	.G/DL	7.5
SODIUM	139		1 1	136-145	MEQ/L	139
CARBON DIOXIDE	29.50	性語。基制		122-33	MEQ/L-	30
SGOT/AST	25	*	- [	15-40	U/L	39
SGPT/AET	73		特制	7-45	Ü/L	39


Director: Lorenz P. Kielhorn, MD

-- End of2Report --

Printed: 03/27/2015 04:43 Case 3:13-cv-00091 Document 563 Filed 05/06/15 Page 7 of 28 PageID #: 4417



2195 SPRING ARBOR ROAD . JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 \* (800) 888-8598 \* FAX (517) 787-1249



ORDERING PHYSICIAN TUCKER, CORTEZ		AME , FRED	SEX M	ACCESSION NO. 201412701824	CONTROL NO. 558220
FACILITY NO. NWCX	оов 09/17/1959	ACC PRIS	OUNT NO. 6407940	DATE COLLECTED 12/08/2014 07:55	DATE RESULTED 12/09/2014 23:46
ennessee DOC 60 State Route 212 IPTONVILLE, TN 38079	EMR ID		MATE ID 244104		

Abnormals S	Summary					
NEUTROPHILS	31.2	LYMPHOCYTE	60.2	HEMOGLOBIN	12.6	75
мснс	30.3	MPV	12.2			
ALK PHOS	139				*	S

Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
FASTING					2	
CBC				col: 12/08/201	4 Sta	tus: F
PLATELET COUNT	211		1 1	150-400	TH/CUMM	W . W . W . P
WHITE BLOOD COUNT	6:44	西海 中北 35	非某事	4:0+10:0	TH/CU MM	
ABSOLUTE NEUTROPHIL CT	2.01	No.		1.56-8.10	x10-3/uL	process of the control of the control
*NEUTROPHILS 1. 4		31.2	1.8	39-81	**	421.13/1
LYMPHOCYTE		60.2	н	14-51	%	
MONOCYTES:	6.48	<b>等取</b> 类 [1]	<b>*</b>		8	
EOSINOPHIL	1.2	£		0-8	%	
BASOPHIES	1.0	(445) · · ·	1.4	052	<b>19</b>	
RED BLOOD CELLS	4.64		1 1	4.41-5.51	M/CU MM	
HEMOGLOBIN	10/07/14 121	12.6	<b>TACT</b>	13.5 17.5	G/DL	
HEMATOCRIT	41.5			41-53	%	
MCV	89.4			80-105	FL	特性器的法
MCH	27.1		1 .1	27-33	PG	
MCHC		30.3	114	30-37	riG/DL //	
RDW	14.1			11.5-14.5	%	
MPV:		12.2	1 11	77.4-10.4	FL	

## **FASTING**

CMP			Col: 12/08/2014	Status: F
ALBUMIN	4.0	1	3.5-5.5	G/DL
ALK PHOS		139 HH	53-128-	Will state of the
TOTAL BILIRUBIN	0.7	1 - 1	0.2-1.2	MG/DL
BUN A	11 ( 4 )		7-18	MG/DL
CALCIUM	9.8	1 1	8.4-10.7	MG/DL
CHLOREDE	1030 3 45 45 45 18 C	ing at strategal	98-107	MEQ/L
CREATININE, SERUM	0.94		0.7-1.3	MG/DL
GER (NON-AER AMER)	89		60-300	me/Min
GFR (AFR AMER)	107	1 1	60-300	mL/MIN


Director: Lorenz P. Kielhorn, MD

Tommic Planifion, FOUP1

continued 3n Next Page 78 of 28 Page 19 #24418



2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249



1000 Or

ORDERING PHYSICIAN TUCKER, CORTEZ	1	AME , FRED	SEX M	ACCESSION NO. 201412701824	CONTROL NO. 558220
FACILITY NO. NWCX	оов 09/17/1959	ACCOUNT NO. PRIS 6407	940	DATE COLLECTED 12/08/2014 07:55	DATE RESULTED 12/09/2014 23:46
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID	inmate id 00244104		·	n n

Test Description	Result	Abnormal	Flag	Reference	Range	Units	Labs
GLUGOSE	70			70-10	5	MG/DL	1,019
POTASSIUM	4.7		1  1	3.5-5	. 1	MEQ/L	me to the street of the street
TOTAL PROTEIN	7.56			6.0-8	31/	G/DL	
SODIUM	139		1. 1.	136-14	-35 TH CORP.	MEQ/L	Andrew Wash and The Company
CARBON DIOXIDE	30		7	22-3	3	MEQ/L	
SGOT/AST	39			15-40	)	U/L	
SGPT/ALT	397			7-45		u/L	
TSH-HIGH SENSITIVITY				col: 12/	08/2014	S	tatus: F
TSH-HIGH SENSITIVITY	3.16			0.465-4	. 68	uU/mL	

12-11-14

Tommie Hamilton, FNP

Director: Lorenz P. Kielhorn, MD

Printed: 12/11/2014 04:31 -- End of #Report --

Pg: 2



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN COLLINS, AMANDA		AME , FRED	SEX M	ACCESSION NO. 201410678516	CONTROL NO. 524739
FACILITY NO. NWCX	оов 09/17/1959	ACCOU PRIS	int no. 6407940	DATE COLLECTED 10/29/2014 11:45	DATE RESULTED 10/31/2014 23:02
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID		4104		

			(9.3)			140
Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
NON-FASTING			Fq. 1	10/00/1004	2 to the time to	
10 PANEL URINE DRUG SCREEN				Col: 10/29/2014	Status:	·
AMPHETAMINE	NEGATIVE	72	1 1	NEGATIVE	NG/ML	
AMPHETAMINE CUTOFF: 1000 NG/ML BARBITURATES CUTOFF: 200 NG/ML	NEGATIVE			NEGATIVE	NG/ML	
BENZODIAZEPINE	NEGATIVE		i i	NEGATIVE	7.0	
BENZODIAZEPINE CUTOFF: 200 NG/ML COCAINE	NEGATIVE			NEGATIVE		
COCAINE CUTOFF: 300 NG/ML				NECATIVE	NG (M	to have been a
METHADONE	NEGATIVE		1 1	NEGATIVE	NG/ML	
METHADONE CUTOFF: 300 NG/ML OPIATES CUTOFF: 300 NG/ML PHENCYCLIDINE (PCP)	NEGATIVE W			NEGATIVE NEGATIVE		
PHENCYCLIDINE CUTOFF: 25 NG/ML PROPOXYPHENE PROPOXYPHENE CUTOFF: 300 NG/ML	NEGATIVE			NEGATIVE	NG/ML.	1.3
CANNABINOIDS	NEGATIVE			NEGATIVE		
CANNABINOIDS CUTOFF: 50 NG/ML URINE GREATININE  URINE GREATININE IS USED TO EVALUATE SAMPLE COLLECTIONS FOR POSSIBLE ADULTERATION: A RESULT GREATER THAN OR EQUAL TO 20 MG/DI IS NORMAL: A RESULT LESS THAN MAY INDICATE POSSIBLE ADULTERATION RECOLLECTION IS SUGGESTED IF URING CREATININE IS LESS THAN 20 MG/DL	20 MG/DL ON OF SAMPLE.		pand	a Collins, PA 4		

NWCX-MC



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN COLLINS, AMANDA	DEAN,	*	SEX M	ACCESSION NO. 201410693473	CONTROL NO. 521034
FACILITY NO. NWCX	<sub>DOB</sub> 09/17/1959	PRIS	NT NO. 6407940	DATE COLLECTED 10/27/2014 07:09	DATE RESULTED 10/29/2014 01:53
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID		TE 1D 4 <b>104</b>	y.	2 0

Abnormals	Summary				
NEUTROPHILS	25.5	LYMPHOCYTE	66.7	HEMOGLOBIN	12.1
MCHC	29.0	RDW	14.6	MPV	12.9

Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
FASTING				5.1. 10/27/2014	Cta	tus: F
CBC				col: 10/27/2014		Lus. F
PLATELET COUNT	192	A CONTRACTOR SOMEON		150-400	TH/CUMM	Late of a feet of the control of the
WHITE BLOOD COUNT.	6.88			74.0-10.0	TH/CULMY	
ABSOLUTE NEUTROPHIL CT	1.74		1 1	1.56-8.10	x10-3/uL	
NEUTROPHILES		25.5	JEKA!	39-81	1% W	
LYMPHOCYTE	A TO THE STATE OF	66.7	H	14-51	%	
MONOCYTES	5.7			0-13.3	%	
EOSINOPHIL	0.9	SEN III IN SOUTH	1 1	0-8	%	- ALCH
BASOPHIES	1.2			0-2	%	@1121.
RED BLOOD CELLS	4.45	5 6	l i	4.41-5.51	M/CU MM	
HEMOGLOBEN:	man variable	. 12.1	100	13.5-17.5.	G/DL	104
HEMATOCRIT	41.9			41-53	%	
MCV.	94.1	<b>F</b> IX 3		80-105	AL S	Marin H
MCH	27.2			27-33	PG	e e
MCHC		29.0		31-37	G/DL 4	
RDW		14.6	H	11.5-14.5	%	Ni-
-MPV	a de la companya de l	" 12.9°	THE	7.4-10.4	FL Child	680

MARTINA Collins, PA-C 0 2014 ferritin melselle vitible appelle

11/4/14




Status: FINAL

PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN COLLINS, AMANDA	NAME DEAN, F		ACCESSION NO. 201409468033	CONTROL NO. 494383
FACILITY NO. NWCX	09/17/1959	ACCOUNT NO. PRIS 6407940	DATE COLLECTED 09/26/2014 07:08	DATE RESULTED 09/27/2014 20:54
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID	INMATE ID 00244104	# E	* * * * * * * * * * * * * * * * * * *

Test Description FERRITIN		Result	Abnormal	Flag	Reference Range col: 09/26/2014	Units Labs Status: F
FERRITIN	NS 2 7	408.9			17.9-464	NG/ML
SERUM IRON					col: 09/26/2014	Status: F
SERUM IRON	A 35. 9	122	*	1 1	50-170	UG/DL
VB12, FOL PANEL	X 1 A				col: 09/26/2014	Status: F
VITAMIN B 12	H 31 V	487.4	(4	1 1	239-931	PG/ML





Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

		201409591835	CONTROL NO. 483168	
FACILITY NO. DOB NWCX 09/17/1959	ACCOUNT NO. PRIS 6407940	DATE COLLECTED 09/15/2014 06:25	DATE RESULTED 09/21/2014 01:54	
ennessee DOC EMRID 160 State Route 212 TPTONVILLE, TN 38079	INMATE ID 00244104			

PLATELET COUNT	Test Description CBC	Result	Abnormal	Flag	Reference Range col: 09/15/2014	Units Labs Status: F	
ABSOLUTE NEUTROPHIL CT 3.23 1.56-8.10 x10-3/uL  NEUTROPHILS 57 39-81 %  LYMPHOCYTE 40 14-51 %  MONOCYTES T 0-13.3 %  EOSINOPHIL 2 0-8 %  REASUPHILS 0'  REASUPHILS 0'  REASUPHILS 0'  RED BLOOD CELLS 4.42 13.5-17.5 G/DL  HEMATOCRIT 42.7 41-5.51 M/CU MM  HEMATOCRIT 42.7 41-53 %  MCV 96.6 80-108 FL  MCH 28.0 27-33 PG  MCHC 29.0 L 31-37 G/DL  RDW 13.4 11.5-14.5 %  MPV  LYMPHOCYTE 12-10-4 FL  CMP C1 09/15/2014 Status: F  ALBUMIN 4.4 3.5-5.5 G/DL  ALK PHOS 126 53-128 U/A  ALK PHOS 126 53-128 U/A  TOTAL BILITUBIN 0.7 0.2-1.2 MG/DL  BIN. 14 7-18 MG/DL  CALCIUM 9.8 8.4-10.7 MG/DL  GIRLORD 1.04 98-107 MGO/L  GER (NON-AFR AMER) 79 80-3000 ME/MIN  GER (NON-AFR AMER) 96 80-3000 ME/MIN  GER (NON-AFR AMER) 96 80-3000 ME/MIN  MIL/MIN	PLATELET COUNT	185		1	150-400	TH/CUMM	
NEUFROPHTLES   57	WHITE BLOOD COUNT	5.66		1 1	4.0-10.0	TH/CU MM	
LYMPHOCYTE	ABSOLUTE NEUTROPHIL CT				1.56-8.10	x10-3/uL	
MONOCYTES   T	NEUTROPHILS	57		k [	39-81	*	
EOSINOPHILE   2	LYMPHOCYTE	40			A Maria Company of the Company of th	%	.y=0
RED BLOOD CELLS	MONOCYTES	1		1	0-13.3	*	
RED BLOOD CELLS       4.42       4.41-5.51       M/CU MM         HEMOGEOBEN       12.4       EL       13.5-17.5       G/DL         HEMATOCRIT       42.7       41-53       %         MCV       96.6       80-1005       FL         MCH       28.0       27-33       PG         MCHC       29.0       L       31-37       G/DL         RDW       13.4       11.5-14.5       %         MPV       12.5       H       74-10.4       EE         CMP       Col: 09/15/2014       Status: F         ALBUMIN       4.4       3.5-5.5       G/DL         ALK PHOS       126       53-128       U/L         TOTAL BILIRUBIN       0.7       0.2-1.2       MG/DL         BÜN       11       7-18       MG/DL         CALCIUM       9.8       8.4-10.7       MG/DL         GHIONIDE       102       98+107       MEQ/EL         CREATININE, SERUM       1.04       0.7-1.3       MG/DL         GFR (NON-AFR AMER)       79       60-300       mL/MIN         GFR (AFR AMER)       96       5D-00.0       ML/MIN	EOSINOPHIL				0-8	%	
HEMOGEOBEN   12.4   EL   13.5-17.5   G/DL     HEMATOCRIT   42.7   41-53   %     MCV   96.6   80-105   FL     MCH   28.0   27-33   PG     MCHC   29.0   31-37   G/DL     RDW   13.4   11.5-14.5   %     MPV   12.5   BL   7-4-10.4   FL     CMP   C31: 09/15/2014   Status: F     ALBUMIN   4.4   3.5-5.5   G/DL     ALK PHOS   126   33-128   U/L     TOTAL BILIRUBIN   0.7   0.2-1.2   MG/DL     BÜN   11.5   7-18   MG/DL     BÜN   21.5   MG/DL     GHLÖRIDE   10.8   8.4-10.7   MG/DL     GHLÖRIDE   10.4   0.7-1.3   MG/DL     GFR (NON-AFR AMER)   79   60-300   mL/MIN     GFR (NON-AFR AMER)   79   60-300   mL/MIN     GFR (AFR AMER)   96   SED.	BASOPHIŬS	01		<del>  1</del>	Ų 0−2	*	
HEMOGEOBEN   12.4   EL   13.5-17.5   G/DL     HEMATOCRIT   42.7   41-53   %     MCV   96.6   80-105   FL     MCH   28.0   27-33   PG     MCHC   29.0   L   31-37   G/DL     RDW   13.4   11.5-14.5   %     MPV   12.5   H   4-10.4   FE     CMP   Col: 09/15/2014   Status: F     ALBUMIN   4.4   3.5-5.5   G/DL     ALK PHOS   126   53=128   U/L     TOTAL BILIRUBIN   0.7   0.2-1.2   MG/DL     BQN   11   7-18   MG/DL     BQN   21   7-18   MG/DL     CALCIUM   9.8   8.4-10.7   MG/DL     CHLOREDE   100   98×107   MEO/L     CREATININE, SERUM   1.04   0.7-1.3   MG/DL     GFR (NON-AFR AMER)   79   60-300   mL/MIN     GFR (AFR AMER)   96   SCD   MIL/MIN     GFR (AFR AMER)   96   SCD   MIL/MIN     GFR (AFR AMER)   96   SCD   MIL/MIN     CREATININE   MERCANICAL   MERCANICAL     GO   300   mL/MIN     MCV   11.5-14.5   %     All 11.5-14.5   %					4.41-5.51	M/CU MM	- W. V.
MCV         96.6         80-105         FL           MCH         28.0         27-33         PG           MCHC         29.0         L         31-37         G/DL           RDW         13.4         11.5-14.5         %           MPV         12.5         HL         3.4-10.4         Ft           CMP         Col: 09/15/2014         Status: F           ALBUMIN         4.4         3.5-5.5         G/DL           ALK PHOS         126         53=128         U/L           TOTAL BILIRUBIN         0.7         0.2-1.2         MG/DL           BÜN         11         7-18         MG/DL           CALCIUM         9.8         8.4-10.7         MG/DL           GHLÖREBER         102         98-107         MEO/LE           CREATININE, SERUM         1.04         0.7-1.3         MG/DL           GFR (NON-AFR AMER)         79         60-300         mL/MINN           GFR (AFR AMER)         96         50-00         60-300         mL/MINN	HEMOGEOBEN		/12.4	EL .	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	G/DL	
MCH         28.0         27-33         PG           MCHC         29.0         L         31-37         G/DL           RDW         13.4         11.5-14.5         %           MPV         12.5         IB         4-10.4         FL           CMP         col: 09/15/2014         Status: F           ALBUMIN         4.4         3.5-5.5         G/DL           ALIC PRIOS         126         53-128         U/L           TOTAL BILIRUBIN         0.7         0.2-1.2         MG/DL           BÜN.         1.1         7-18         MG/DL           CALCIUM         9.8         8.4-10.7         MG/DL           GHLOREDS         102         98-107         MEQ/L           CREATININE, SERUM         1.04         0.7-1.3         MG/DL           GFR (NON-AFR AMER)         79         60-300         mL/MIN           GFR (AFR AMER)         96         SERUM         60-300         mL/MIN	HEMATOCRIT	42.7		$\bot \bot$	Value 14 regulation ass	<b>%</b>	, i
MCHC   29.0   13.4   11.5-14.5   %   MPV   12.5   H   7.4-10.4   Ft   CMP   Col: 09/15/2014   Status: F   ALBUMIN   4.4   3.5-5.5   G/DL   ALK PHOS   126   53=128   U/4   TOTAL BILIRUBIN   0.7   0.2-1.2   MG/DL   MG/DL   CALCIUM   9.8   8.4-10.7   MG/DL   CALCIUM   9.8   8.4-10.7   MG/DL   CALCIUM   9.8   8.4-10.7   MG/DL   CREATININE, SERUM   1.04   0.7-1.3   MG/DL   GFR (NON-AFR AMER)   79   60-300   mL/MIN   GFR (AFR AMER)   96   MED   MED   MED   MIN	MCV	96.6				FL 1	32 10
RDW	MCH	28.0	of the Contract of the State of	0.00	Contract Contract Contract Contract	PG	
MPV	MCHC		29.0		FE - 1 10 SH 1 500 1 1 1 1 1 1 1 1 1 1	G/DL	18 10 50
CMP  ALBUMIN  4.4  ALK PHOS  TOTAL BILIRUBIN  0.7  BUN  CALCIUM  9.8  HOG/DL  CALCIUM  9.8  102  CREATININE, SERUM  1.04	THE SECRETARY SERVING AND ADDRESS OF THE SECRETARY SERVING AND ADDRESS OF THE SECRETARY SERVING AND ADDRESS OF THE SECRETARY SECRETARY SERVING AND ADDRESS OF THE SECRETARY SECR	13.4	rangungan da kabupatèn da kabupat	Notice of all	a compression and a compression of the compression	TOTAL PROPERTY OF THE PROPERTY OF THE	76
ALBUMIN 4.4 3.5-5.5 G/DL  ALK PHOS	The state of the s		12.15 E	ill.	ASSESSED AND CARROLL AND ASSESSED AND ASSESSED AND ASSESSED ASSESSED.	EMPTO PROCESS OF THE PROPERTY OF THE	, 97C
ALK PHOS 126 53-128 U/L  TOTAL BILIRUBIN 0.7 0.2-1.2 MG/DL  BUN 11 7-18 MG/DL  CALCIUM 9.8 8.4-10.7 MG/DL  CHLORIDE 102 98-107 MEO/L  CREATININE, SERUM 1.04 0.7-1.3 MG/DL  GFR (NON-AFR AMER) 79 60-300 ML/MIN  GFR (AFR AMER) 96 SED 70 60-300 ML/MIN							
TOTAL BILIRUBIN 0.7 0.2-1.2 MG/DL  BÜN 11 7-18 MG/DL  CALCIUM 9.8 8.4-10.7 MG/DL  GHLORTDE 102 98-107 MEQ/L  CREATININE, SERUM 1.04 0.7-1.3 MG/DL  GFR (NON-AFR AMER) 79 60-300 mL/MIN  GFR (AFR AMER) 96 SFD 10 60-300 mL/MIN	HE BOOK A PRODUCTION OF A MARKET THE ALL THE A PRODUCT AND A PROPERTY OF	The rest of the second			the control for the control of the control of the control of	and the series of the first of the	u di gari
BUN 11 7-18 MG/DL  CALCIUM 9.8 8.4-10.7 MG/DL  CHLORIDE 102 98-107 MEO/L  CREATININE, SERUM 1.04 0.7-1.3 MG/DL  GFR (NON-AFR AMER) 79 60-300 mL/MIN  GFR (AFR AMER) 96 SFD 7 60-300 mL/MIN	to the military property of the property of the property of the	中の他ではは金属性を用いている。		A TE	and a series of the control of the c	A MONTH OF THE PROPERTY OF THE PARTY OF THE	10 mg
CALCIUM 9.8 8.4-10.7 MG/DL  GHLORIDE 98-107 MEQ/L  CREATININE, SERUM 1.04 0.7-1.3 MG/DL  GFR (NON-AFR AMER) 79 60-300 mL/MIN  GFR (AFR AMER) 96 SFD 60-300 mL/MIN	7 STANGOS PER MESIS, AND PROPERTY OF STANFORD ASSOCIATION OF STANFORD OF STANF	HILL D. THEOLOGICAL CONTROL CONTROL	en e	l Villa	A ST AND SWARDS INTEREST BUTTON IN CO.	网络比喻的战争。 计连续控制 计图 化压力	e N. s., i
## CREATININE, SERUM 1.04   98-107   MEQ/L  CREATININE, SERUM 1.04   0.7-1.3   MG/DL  GFR (NON-AFR AMER) 79   60-300   mL/MIN  GFR (AFR AMER) 96   SFD (1/2)   60-300   mL/MIN	The state of the s	State Committee and Address		<b>在</b> 建模	The state of the second of the		
CREATININE, SERUM  1.04  0.7-1.3  MG/DL  GFR (NON-AFR AMER)  79  GFR (AFR AMER)  96  SFD (NON-AFR AMER)  60-300  mL/MIN	1. The let fail the agent his factors agree to Contact process and the contact and contact and the contact and the	eranical and an artist of the second	Water of Alexander	(3 - 12ja)	ON CERTAIN THEIR COMPONENT OF THE WARRING	SAME AS SAME AND ASSAULT OF THE SAME AS A SAME A	10 to 10
GFR (NON-AFR AMER) 96 SEPANO 60-300 mL/MIN	DATAPASE TO A TANDON SECTION AND ARREST OF THE SECTION OF THE SECT	2000年,1200年的大型的1000年,1000年的1000年的1000年的1000年的1000年的1000年的1000年的1000年的1000年的1000年的			DOMESTIC ASSESSMENT SERVICES	SETT TOTAL CONTRACTOR	
GFR (NON-AFR AMER) 96 SEPANO 60-300 mL/MIN	TO A SECURITION OF THE PROPERTY OF THE PROPERT	1.04	ada at 2 xx	$\mathcal{Y}\setminus$	CONTRACTOR OF CONTRACTOR OF STREET, AND CONT	SET PROBLEMENT OF THE STORY STORY	量性;
	CONT. The Property of the Conference of the Conf	19 1 - 10 P	De one	D.	ALCO AND MEDICAL LANGUAGE. ASSESSED	and the property of the second control of th	M. A. W.
POTASSIUM 4.4 WCX   3.5-5.1 MEQ/L	and the Well I response to the Manual Artist to	The second secon	SEPANO	- A-C	CONTRACTOR AND AND AND A STORY	Bankstall added a distant	
PUIASSIUM 4.4 TO A DEQ/L		/o W	WO 2014		A MARIA HE AND CONTRACTOR	The state of the s	\$ 4
	TOTAL PROTEIN	4.4	Y-Me		6.0-8.3	MEQ/L G/DL	00 00



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN COLLINS, AMANDA	1.55	AME , FRED	SEX M	ACCESSION.NO. 201409591835	CONTROL NO. 483168
FACILITY NO. NWCX	09/17/1959	ACCOUNT NO. PRIS 6407940		DATE COLLECTED 09/15/2014 06:25	DATE RESULTED 09/21/2014 01:54
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID	INMATE ID 00244104			*)

Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
SODIUM	137			136-145	MEQ/L	SERVICE DAL VA
GARBON DIOXIDE	27		洲之事	22-33	MEQAL	1000
SGOT/AST	38		1	15-40	U/L	Signatura de la Maria della de
SGPP/ART	34	Jan Jan Jan Baran Sa Hala	المسال	7-45	N/F	A SALAME
URINE (MICRO IF IND)				col: 09/15/201	4 Sta	tus: F
PH	6.0		1 1	5.0-8.0	and the second	. Our Julies of the
PROTEIN (ALBUMIN)	NEGATIVE				41 False, F	
GLUCOSE	NEGATIVE		L	erantine and responsible of the contract	ille Street and second so	annound abt
KETONES (ACETONE)	NEGATIVE		1.0			
BILIRUBIN (URINE)	NEGATIVE			natural est de estima escripturat y messa. Estado	io Salakum na kesifilisi	region intercents (35) Media.
UROBILINOGEN:	∛0.2 · ⊨			0.2-1.0		
BLOOD (OCCULT)	NEGATIVE	American state out to the confidence		rows in wheth survivorsation 1996	entre de la compa	/ V to 2004-195-75
LEUKOCYTE ESTERASE	NEGATIVE					
NITRITE	NEGATIVE	West of the development		on commence of the manager	n di Santa da Maria Santa di	The second of the second
COLOR	YELLOW				24.0 M 16.0 F	Fig. (Sept.) (Fig.)
APPEARANCE	CLEAR	all out to the superior of the state of the		TO THE FEBRUARY STORES AND A STORES OF THE STORES AND A STORES OF THE STORES AND A STORES OF THE STORES AND A	5073646377NF-5004	C. 1 1944 - 56 1935
SPECIFIC GRAVITY	1.015	<b>"我我就能</b>		1.003-1.030		
MICROSCOPIC COMMENT	MICROSCOPI	C NOT IND		3		

W 2012

NACA-MC



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

	ING PHYSICIAN		AME	SEX	ACCESSION NO.	CONTROL NO.
	TON, TOMMIE		FRED	M	201408542136	453626
	CILITY NO. NWCX	оов 09/17/1959	ACCOUNT PRIS	6407940	DATE COLLECTED 08/12/2014 06:44	DATE RESULTED 08/14/2014 04:58
Tennessee DOC	- 212	EMR ID	INMATE		1	
960 State Rout TIPTONVILLE, T			00244	104		
			* * * * * * * * * * * * * * * * * * * *			
Abnormals S						
NEUTROPHILS	25.2	LYMPHOCYTE	65.1		RED BLOOD CEL	
HEMOGLOBIN	12.4	HEMATOCRIT	40.2	n 9	MCHC	30.8
RDW	15.2	MPV	12.3			
ALK PHOS	137	SGOT/AST	41			
Test Descrip	otion	Result	Abnormal	Flag Re	eference Range ( col: 08/12/2014	Inits Labs Status: F
PLATELET COU	NT	228		1-1-	150-400	H/CUMM
WHITE BLOOD	COUNT	7.76			於《熱陰》。 (對義 漢字 [1] () 於"以如	H/CU MM
ABSOLUTE NEU	TROPHIL CT	1.96	I HOLD IN THE REPORTED IN	1	스트 닭에 화장하다 깨끗했다니다 그 경상	10-3/uL
NEUTROPHULS	CYMPATER	THE PARK SECTION	25.2	47606	39-81	
LYMPHOCYTE	e interes producti establica de la competen		65.1	ла жымсан. 1 н	14-51 %	Normandelisterister i Lucarra del Co
MONOCYTES	A CONTRACTOR	Kir 74 726 (177)			0+13.3	为。新疆 <b>对</b> 数是1961年6月17年
EOSINOPHIL		1.0		Herricollerias 	0-8 χ	
PASSIPUTIE		THE TAX TO SEE			Saffanglæstet Medeles	SWINDSON CHANGE CONTRACTOR
RED BLOOD CEI	116		4.31	THE P	estamble to engages that did to prest qu	
<b>安约是为证据的人类自由专门的</b> 第二元分			CONTRACTOR MARKET	AND STREET	10.3 EAL 2 100 (2 PARTO)	/CU MM
HEMOGEOBEN,		A second control of the second control of th	12.4	LL	NAME OF THE OWNER	/DL
HEMATOCRIT	PERSONAL CENTRES	es summer de la	40.2	LL	41-53 %	Historia di Maria Angaras di Marada
MeV	数上方面影響	E 93.3	<b>10</b>		positions with a sile of a control	
MCH era exaction styles recognise	Franklyka (kurt Utura Takkuwa Kur)	28.7	ranam interestambang	MANAGER STATE AND	27-33 p	G
MCHC	1. 情况	And American	30.8		31-37	/DL
RDW			15.2	- H-	11.5-14.5 %	
MPV	19-66		12.3	l'Hale	7.4-10.4 F	g i i i i i i i i i i i i i i i i i i i
CMP					col: <b>08/12/201</b> 4	Status: F
ALBUMIN		4.3			3.5-5.5 G	/DL
ALK PHOS H	的"数别",		137	HH (*	APALA MELIKAT KANTAR	ŹĠ
TOTAL BILIRUE	BIN	0.7	setMicrostru e fatorisse testic	MERCENSHOWN CORP.	CHARLOW YOUR TOTAL STREET, STR	G/DL
BUN 2		10 Yalisa		Maria 1	ATTACHMENT OF STREET	G/DL
CALCIUM	CONTRACTOR	9.8		ia nekorekarenek 	CHILD S INTRODUCED STREET	G/DL
CHLOREDE	de de Alberta	Nos.		10.50	DESCRIPTION OF THE	THE WAR PROPERTY OF THE PARTY O
CREATININE, S	SERUM	1.04	20.30mm (15.00mm)	Dest: 24 25 23 	eller Anna Santa Santa Santa Control of the eller	EQ/D
GER (NON-AFR	entartementarieren anvecasioneren	70	Maria Wax	i kalit "s	の 表的なな 気造し 医・経され 成熟する	G/DL
GFR (AFR AMER	Secretary of Chances	05		Maria S	STANDARD STANDARD STANDARD	L/MIN
CAPA AMER	TALIZONI I	95	(%) (1) (4) (8) (4) (8) (8) (8) (8) (8) (8) (8) (8) (8) (8		SHEWELD CONTROLLED TO THE SECOND	L/MIN
DESCOSE ( )	。	₹ 85.	######################################		70-105 M	G/DC
•	• •	Director: Lor	enz P. Kielhori	n, MD	. "	-14



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN HAMILTON, TOMMIE		AME	SEX M	ACCESSION NO. 201408542136	CONTROL NO. 453626
FACILITY NO. NWCX	оов 09/17/1959	PRIS	OUNT NO. 6407940	DATE COLLECTED 08/12/2014 06:44	DATE RESULTED 08/14/2014 04:58
Tennessee DOC 960 State Route 212 TIPTONVILLE, TN 38079	EMR ID		MATE ID 244104		

Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
POTASSIUM	4.6		1 1	3.5-5.1	MEQ/L	a section of the sect
TOTAL PROTEIN	8.0	oliffe Santologia		6.0-8.3	G/DL 🕅	
SODIUM	140	780	1 1	136-145	MEQ/L	e e creteri secono
CARBON DIOXIDE	16 Kar 21		1331	22-33	MÉQ/L	行旗
SGOT/AST		41	HH-	15-40	U/L	a populating to agreement and
SGPT/ALT	40			7-45-1	WU/L	
PROSTATE SPECIFIC AG				col: 08/12/2014	Sta	tus: F
PROSTATE SPECIFIC AG	0.475		1 1	0-3.2	NG/ML	90.75

8-25-14



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN THOMPSON, DONALD	100 A	AME FRED	161	SEX M	ACCESSION NO. 201404367818	CONTROL NO. 339821
FACILITY NO. NECX	DOB 09/17/1959	ACCC PRIS	6407940		DATE COLLECTED 04/14/2014: 10:00	DATE RESULTED 04/17/2014 12:31
Tennessee DOC 5249 Highway 67 West MOUNTAIN CITY, TN 37683	EMR ID		1ATE ID 144104			* =

Abnorma	ls	Summary
HED D CODE	40	DOCTT

Test Description

HEP B CORE AB

POSITIVE

Abnormal

Reference Range

NON-FASTING

HEP B CORE AB

Status: F

HEP B CORE AB

POSITIVE | A |

**NEGATIVE** 

col: 04/14/2014





2195 SPRING ARBOR ROAD \* JACKSON, MICHIGAN 49209 PHONE (517) 787-9200 \* (800) 888-8598 \* FAX (517) 787-1249

ORDERING PHYSICIAN		AME , FRED	SEX M	ACCESSION NO. 201402239046	281701
BERNARD, CLEMENT	DEAN	ACCOUNT I	NO.	DATE COLLECTED	DATE RESULTED 02/25/2014 16:13
FACILITY NO. NECX	09/17/1959		407940	02/12/2014 11:23	02/25/2014 10.1
nnessee DOC 49 Highway 67 West UNTAIN CITY, TN 37683	EMR ID	INMATE 1 002441			nits Labs

Labs Reference Range Units Abnormal Flag Result Test Description Status: F col: 02/12/2014 NON-FASTING HCV RNA GENOTYPE, LIPA GENOTYPE 1B HCV RNA GENOTYPE, LIPA The method used in this test is RT-PCR and reverse hybridization (Line Probe) of the 5' UTR and core region of This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. performance of the test.
Quest Diagnostics also offers the AccuType(R) IL28B test,
which can help stratify HCV-infected individuals into those
who are predisposed to respond more favorably and those who
are predisposed to respond less favorably to standard HCV
are predisposed to respond less favorably to predicts
therapy. A favorable IL28B genotype (ie, CC) predicts
improved treatment response for individuals infected with
HCV genotype 1. Reference: Clin Gastroenterol Hepatol.
2011;9:344-350. To order the IL-28B test please submit a new
whole blood sample for test code 90251.
http://education.questdiagnostics.com/faq/HCVGenotyping FEB 2 6 2014 http://education.questdiagnostics.com/faq/HCVGenotyping
THE METHOD USED IN THIS TEST IS RT-PCR AND REVERSE
HYBRIDIZATION (LINE PROBE) OF THE 5' UTR AND CORE REGION OF THE HCV GENOME. TEST PERFORMED AT QUEST DIAGNOSTICS 4444 GIDDINGS RD status: F col: 02/12/2014 48326-1561 MI AUBURN HILLS, AUTH REQUIRED QUESTION status: F col: 02/12/2014 AUTH REQUIRED QUESTION HCV RNA DONA WILL FOLLOW HCV RNA bDNA TEST PERFORMED BY SIEMENS CLINICAL LABORATORY 725 POTTER STREET BERKELEY CA 94710-3614 (800)434-2447 DIRECTOR: WILLIAM P JOSEPH, MD status: F col: 02/12/2014 < 615 IU/ML NORMAL RANGE: 9.5-11.5 PT/INR 10.7 PROTHROMBIN TIME INREDICE

THERAP: 2.0-3.0 DVT/PE/MI/TISS HT-VAL/VAL HT DIS/ATR
2.5-3-5 CARDIO EMBOLUS/MECH/HT VAL

Director: Lorenz P. Kielhorn, MD

-- End of Report --



Status: FINAL

Labs

Status: F

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN BERNARD, CLEMENT	NAME SEX DEAN, FRED M		ACCESSION NO. 201311851477	CONTROL NO. 209567	
FACILITY NO. NECX	оов 09/17/1959	ACCOUNT NO. PRIS 6407940	DATE COLLECTED 11/20/2013 10:16	DATE RESULTED 11/25/2013 08:12	
Tennessee DOC 5249 Highway 67 West MOUNTAIN CITY, TN 37683	EMR ID	INMATE ID. 00244104			

Abnormals	Summary
HPT TOG ARS	2.21

GREATER THAN 0.99 . . . . . POSITIVE

HPI IgG ABS	2.21				20.1	
Test Descri	iption	Result	Abnormal	Flag F	Reference Range	Units
NON-FASTING					8 # #	
H. PYLORI I	IgG/IgM/IgA	· · · · · · · · · · · · · · · · · · ·			col: 11/20/201	3 s
HPI IGG ABS		238	2.21	н	< 0.91	Index
Less t	than 0.91 . - 1.09 er than 1.09	H. pylori IgG Ab Negative Equivoca Positive < 0.89	ı]		< 0.89	Index
HPI IGA ABS		< 0.89	Tan Characterists (NO)	i i	< 0.89	Index
Less t 0.89 - Greate H. pylori I performance Diagnostics	than 0.89 - 0.99 er than 0.99 IgM Abs: This characterist Nichols Inst	H. pylori Igm and Ig Negative Equivoca Positive s test(s) was develop tics have been determ titute, Valencia, CA. o the analytical perf	ed and its ined by Quest Performance		F	
Basel Kas 27027 Tou Valencia, CLIA 05D REFERENCE RA LESS THAN 0.	agnostics Nic shlan M.D., F urney Road , CA 91355-53 00550302 ANGE FOR H. P .89	PYLORI IGG, IGM AND I		8 0 6 8 2 X		
test.  @ Test Perf Quest Dia Basel Kas 27027 Tou Valencia, CLIA 05D REFERENCE RA	Formed By: agnostics Nic shlan M.D., F urney Road CA 91355-53 00550302 ANGE FOR H. P 89	chols Institute FCAP., Laboratory Dir 386 PYLORI IgG, IgM AND I	rector	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8		

MOV 2 6 2013

Dr Clement Bernard, MD

Director: Lorenz P. Kielhorn, MD

Printed: 11/25/2013 12:55 -- End of Report -- Printed: 14



Status: FINAL

2195 SPRING ARBOR ROAD • JACKSON, MICHIGAN 49203 PHONE (517) 787-9200 • (800) 888-8598 • FAX (517) 787-1249

ORDERING PHYSICIAN CHAFIN, WANDA		, FRED	SEX M	ACCESSION NO. 201309964146	CONTROL NO. 150897
FACILITY NO. NECX	DOB 09/17/1959	ACC PRIS	OUNT NO. 6407940	DATE COLLECTED 09/11/2013 09:58	DATE RESULTED 09/12/2013 23:17
Tennessee DOC 5249 Highway 67 West MOUNTAIN CITY, TN 37683	EMR ID		MATE ID 244104		ž *
Abnormals Summary					

Abnormals S	ummary					
NEUTROPHILS	35.7		LYMPHOCYTE	55.4	HEMOGLOBIN	12.6
MCHC	29.6	200	MPV	12.5	- 3	
ALK PHOS	136	= 820 00	8 0	P2	25	

Test Description	Result	Abnormal	Flag	Reference Range	Units	Labs
NON-FASTING					- 8	
CBC				Col: 09/11/2013	Sta	tus: F
PLATELET COUNT	189	armenta variational accessors		150-400	TH/CUMM	
WHITE BLOOD COUNT	6,62		1 1	440-1040	TH/CD MM	
ABSOLUTE NEUTROPHIL CT	2.36		-	1.56-8.10	x10-3/uL	
NEUTROPHILS		35.7	L.	39-81	*	
LYMPHOCYTE		55.4	H	Cole. 7 14-51	%	
MONOGYTES	7.2		1.	0-13.3	%	
EOSINOPHIL	0.9	**************************************		0-8	%	The state of the s
BASOPHILIS	0.8			0-2	<b>%</b> 10	
RED BLOOD CELLS	4.45	Children and a second	İ	4.41-5.51	M/CU MM	(2015年) · 111年 · 11年 · 111年 ·
CHEMOGLOBIN	200	12.6	PLL.	H. 3 13.5-17.5	G/DE	
HEMATOCRIT	42.6	the control of the state of the second	SE SOSSION	41-53	%	0-16-
MGVIERTA	95.8	MARINE PROPERTY	12.21	80-105	AZM SANTO	MICH
MCH	28.4	EARLY WELD WELL STORY	Skor-scarafti	27-33	PG	11035
MCHC		29 6	I PAG	21. <b>5</b> : 31-37	G/DL	9-16-13 NCC4 1025
RDW	13.5	BATE OF PARTY OF THE PARTY	I I I	11.5-14.5	ALL STATES OF SHIPPER	MIL IN
News to the contract of		Strebana e	12-0-2211	7.4-10.4	% ************************************	CMIT
CMP				col: 09/11/2013	Taribas Stat	us: F
ALBUMIN	4.3		1 1	3.5-5.5		
Alkaphos and	LENGTH NAME OF	106	HH.	W 53-128	G/DL	THAT FULL IS
TOTAL BILIRUBIN	0.7	e de la compania de La compania de la compania del compania del compania de la compania del compania de la compania de la compania del compania del compania del compania del compania del la compania del  compania del compania del compania del compania del compania de		0.2-1.2	u/Ē	19. 19. 12.
RIN	F 32			C. ARLENNIS CO. Section Co. Land Properties	MG/DL	VMD HERVEL
CALCIUM	9.5		15, 25, 14	7-18	MG/DL	684XE-251744
TO ARREST MARKET SPERMENT OF ALMOST AND THE WORLD SERVICE AND ARREST ARREST ARREST AND ARREST AND ARREST AND ARREST ARRES	sa sente victoristano di la propieta di provincio	#\$2%(F/E) Y977 - 44	0.094.68	8.4-10.7	MG/DL	a farking to be the
ACHLORIDE	104		1 20%	98-107	MEQZL	
CREATININE, SERUM	0.95		-  -  -	0.7-1.3	MG/DL	
-GFR (NON-AFR AMER)	88	<b>19</b>		60-300	mC/MIN	
GFR (AFR AMER)	106	NAME OF TAXABLE PARTY OF TAXABLE OF	a. Adamana sa	60-300	mL/MIN	Paline and sharenes as
* GPUGOSE ATT TO THE TOTAL ATTENDED	98 (84 ) (6)			70-(105	MG/DL	

Director: Lorenz P. Kielhorn, MD

Printed: 09/13/2013 02:14 Cont

Continued on Next Page 15



BERNARD, CLEMENT

T0318 - CORCMS NORTHEAST

5249 HIGHWAY 67 WEST,

MOUNTAIN CITY, TN 37683

Acct #: (T0318)

P: 423-727-7387

MO

0.98

80

97

12.2

9.0

7.2

DEAN, FRED

09/17/1959 DOB: Age: 53 Yrs

Sex:

Medical Record:

Inmate ID:

244104

Address:

, TN

Specimen ID: 104928914

Date Of Report: 05/18/2013 06:38

Date Collected: 05/17/2013 04:04

Date Received: 05/17/2013 23:34

Notes: PATIENT FASTING

CLINICAL REPORT

(May not contain all abnormal results; narrative results may not have Clinical Abnormalities Summary: abnormal flags. Please review entire report.)

ALT

Creatinine

BUN/Creat Ratio

e-GFR, African American

e-GFR

Calcium

Uric Acid

42 HI

11.3 LO

GGTP-

129 HI

35.9 LO

0.97

81

98

10.3

9.4

6.3

01/29/2013

01/29/2013

01/29/2013

01/29/2013

01/29/2013

08/24/2012

HGB **HCT POLYS** 21.0 LO LYMPHS 66.7 HI -----\* CHEMISTRY \*-----Previous Result Dage Reference Total Protein 7.3 5.9-8.4 g/dL 7.6 01/29/2013 **Albumin** 4.1 3.5-5.2 g/dL 4.4 01/29/2013 Globulin 3.2 1.7-3.7 g/dL 3.2 01/29/2013 A/G Ratio 1.3 1.1-2.9 1.4 01/29/2013 Glucose 82 70-99 88 01/29/2013 mg/dL Sodium 140 133-145 mmol/L 139 01/29/2013 Potassium 4.6 3.3-5.3 mmol/L 01/29/2013 4.1 Chloride 103 96-108 mmol/L 101 01/29/2013 C02 22-29 26 mmol/L 27 01/29/2013 BUN 12 6-20 mg/dL 10 01/29/2013

0.90-1.30

10.0-28.0

8.6-10.2

3.4-8.5

>60

>60

mg/dL

mL/min

mL/min

mg/dL

mg/dL

Iron	81	45-160	ug/dL	76	08/24/2012
Bilirubin, Total	0.3	0.1-1.0	mg/dL	0.5	01/29/2013
LD	191	135-225	U/L	187	08/24/2012
Alk Phos	111	40-156	U/L	135	01/29/2013



BERNARD, CLEMENT

T0318 - CORCMS NORTHEAST

0 5249 HIGHWAY 67 WEST,

MOUNTAIN CITY, TN 37683

Acct #: (T0318)

P: 423-727-7387

DEAN, FRED

DOB: 09/17/1959 Age: 53 Yrs

Sex:

Medical Record:

Inmate ID: 24410

Address:

, TN

P:

MO

Specimen ID: 104928914

Date Of Report: 05/18/2013 06:38

Date Collected: 05/17/2013 04:04

Date Received: 05/17/2013 23:34

# CLINICAL REPORT

Test	Result Abnorm		Unitis	Previous Result	Date
NOTE: New reference ranges 11/26/12.	for Alkaline Phospha	tase effective	, M	9	3
AST	39	<40	U/L	51 HI	01/29/201
PHOSPHORUS	4.4	2.7-4.5	mg/dL	4.1	08/24/202
ALT	42 HI	<41	U/L	51 HI	01/29/201
GGTP	129 HI	10-71	U/L	123 HI	08/24/202
-* CARDIOVASCULAR/LIPIDS	*	19112-X			
Cholesterol	163	<200	mg/dL	168	08/24/203
Triglycerides	148	<150	mg/dL	130	08/24/201
HDL CHOL., DIRECT	45	>40	- a	51	08/24/201
HDL as % of Cholesterol	28	>14	<b>%</b> 5 <sub>0, 5</sub> 5 12.	30	08/24/201
Chol/HDL Ratio	3.6 1.96	7 <7.4	. +	3.3	08/24/201
LDL/HDL Ratio	1.96	<3.56		1.78	08/24/201
LDL Cholesterol	88	<100	mg/dL	91	08/24/201
VLDL, CALCULATED	30	7-32	mg/dL	26	08/24/201
* HEMATOLOGY *					
WBC - E	5.92	3.40-11.80	x10(3)/uL	6.59	01/29/201
RBC	4.22	4.20-5.90	x10(6)/uL	4.56	01/29/201
HGB	11.3 L	12.3-17.0	gm/dL	12.8	01/29/201
нст	35.9 L	39.3-52.5	%	37.5 LO	01/29/201
MCV	85.1	80.0-100.0	- fL	82.2	01/29/201
MCH	26.8	25.0-34.1	pg	28.1	01/29/201
MCHC	31.5	29.0-35.0	gm/dL	34.1	01/29/201
RDW	13.6	10.9-16.9	%	14.1	01/29/201
POLYS	21.0 L(	36.0-78.0	%	23.9 LO	01/29/201
POLYS, ABS. COUNT	1.24	1.22-9.20	x10(3)/uL	1.58	01/29/201
LYMPHS	66.7 H	12.0-48.0	%	66.3 HI	01/29/201
LYMPHS, ABS. COUNT	3.95	0.41-5.66	x10(3)/uL	4.37	01/29/201
MONOS	11.5	0.0-13.0	%	8.2	01/29/201
MONOS, ABS. COUNT	0.68	0.17-1.42	x10(3)/uL	0.54	01/29/201
EOS	0.5	0.0-8.0	%	0.9	01/29/201
EOS, ABS. COUNT	0.03	0.03-0.94	x10(3)/uL	0.06	01/29/201



BERNARD, CLEMENT

T0318 - CORCMS NORTHEAST

5249 HIGHWAY 67 WEST,

MOUNTAIN CITY, TN 37683

O Acct #: (T0318)

MO

P: 423-727-7387

DEAN, FRED

DOB: 09/17/1959 Age: 53 Yrs

Sex: M

Medical Record:

Inmate ID:

244104

Address:

, TN

P:

Specimen ID: 104928914

Date Of Report: 05/18/2013 06:38

Date Collected: 05/17/2013 04:04

Date Received: 05/17/2013 23:34

# CLINICAL REPORT

rest. It is a second of the second	Result Abnormal	Reference	Unites	Previous Resu	lit Datie
BASOS	0.3	0.0-2.0	%	0.5	01/29/2013
BASOS, ABS. COUNT	0.02	0.00-0.24	x10(3)/uL	0.03	01/29/2013
IMMATURE GRANULOCYTES	0.0	0.0-1.6	%	0.2	01/29/2013
Platelet Count	215	144-400	x10(3)/uL	222	01/29/2013
MPV	11.2	8.2-11.9	fL	12.0 HI	01/29/2013

NOTE: One or more parameters of the CBC reported for this accession require a MANUAL peripheral smear differential review and/or cell count. This has been performed as per our protocol and commented on the report, if necessary. This review also included RBC morphology and platelet estimation.





MOORE, DAVID

T0318 - CMS NORTHEAST

D 0 5249 HIGHWAY 67 WEST,

MOUNTAIN CITY, TN 37683

Acct #: (·T0318)

P: 423-727-7387

DEAN, FRED

DOB: 09/17/1959 Age: 53 Yrs

М Sex:

Medical Record:

Inmate ID:

244104

Address:

, TN

MO

Specimen ID: 103142196

Date Of Report: 01/30/2013 06:59

Date Collected: 01/29/2013 07:45

Date Received: 01/29/2013 23:49

# CLINICAL REPORT

				the state of the s	The same of the sa
* HEMATOLOGY *	14241		,		
inst	Resolf Abn	ormal Reference	Units	Tradition (Court	Date -
WBC	6.59	3.40-11.80	x10(3)/uL	7.10	08/24/2012
RBC	4.56	4.20-5.90	x10(6)/uL	4.24	08/24/2012
HGB	12.8	12.3-17.0	gm/dL	11.4 LO	08/24/2012
нст	a., a., 37.	5 LO 39.3-52.5	%	35.0 LO	08/24/2012
MCV	82.2	80.0-100.0	fL	82.5	08/24/2012
MCH	28.1	25.0-34.1	pg	26.9	08/24/2012
MCHC	34.1	29.0-35.0	gm/dL	32.6	08/24/2012
RDW	14.1	10.9-16.9	%	14.0	08/24/2012
POLYS	23.	9 LO 36.0-78.0	%	29.8 LO	08/24/2012
POLYS, ABS. COUNT	1.58	1.22-9.20	x10(3)/uL	2.11	08/24/2012
LYMPHS	66.	3 HI 12.0-48.0	%	59.0 HI	08/24/2012
LYMPHS, ABS. COUNT	4.37	0.41-5.66	x10(3)/uL	4.19	08/24/2012
MONOS	8.2	0.0-13.0	%	9.7	08/24/2012
MONOS, ABS. COUNT	0.54	0.17-1.42	x10(3)/uL	0.69	08/24/2012
EOS	0.9	0.8-8.0	%	1.0	08/24/2012
EOS, ABS. COUNT	0.06	0.03-0.94	x10(3)/uL	0.07	08/24/2012
BASOS	0.5	0.0-2.0	%	0.4	08/24/2012
BASOS, ABS. COUNT	0.03	0.00-0.24	x10(3)/uL	0.03	08/24/2012
IMMATURE GRANULOCYTES	0.2	0.0-1.6	%	0.1	08/24/2012
Platelet Count	222	144-400	x10(3)/uL	249	08/24/2012
MPV		9 HI 8.2-11.9	fL	11.5	08/24/2012

#### POIKILOCYTOSIS 2+

NOTE: One or more parameters of the CBC reported for this accession require a MANUAL peripheral smear differential review and/or cell count. This has been performed as per our protocol and commented on the report, if necessary. This review also included RBC morphology and platelet estimation.

01-31-2013 PO1:10

Katherine Goff, MD

LabCorp Birdingnam

1801 First Avenue South, Birmingham, AL 35233-1935

Phone: 205-581-3500

**SPECIMEN** TYPE PRIMARY LAB | REPORT STATUS 274-766-2195-1 S COMPLETE Page #: 1

ADDITIONAL INFORMATION

FASTING: N DOB: 9/17/1959

PATIENT NAME AGE(YR./MOS.) SEX DEAN, FRED M

PT. ADD.:

DATE OF COLLECTION TIME DATE RECEIVED DATE REPORTED TIME 9/30/2008 10/02/2008 11:50 10/03/2008 17:05

TEST

**CLINICAL INFORMATION** CD-41295410023 PHYSICIAN ID. NPI PATIENT ID. SATOR: I 244104 ACCOUNT: Riverbend Maximum Security Institution

7475 Cockrill Bend Indr Rd NASHVILLE

ACCOUNT NUMBER: 41839940 LIMITS LAB

HBsAb+Ag+HCVAb HBsAq Screen Confirm. indicated Negative 01 HBsAg Confirmation Positive 01 Hep B Surface Ab <0.1 Index Value 0.00 - 0.9901 atus of Immunity Anti-HBs Level Inconsistent with Immunity 0.00 - 0.99Consistent with Immunity >0.99

RESULT

8946

An Index Value of 1.00 is equivalent to 10 mIU/mL. However the magnitude of the Index Value is not indicative of the total amount of antibody present.

\*\*Please note reference interval change\*\*

>11.0 H s/co ratio 0.0 - 0.9

01

37209-0000

Indicates past or present HCV infection; Immunoblot testing not performed. Samples with high s/co ratios (>10.9) confirm positive (95%), but <5 out of 100 might represent false-positives. PCR testing can be requested if indicated (requires an additional sample to be submitted). Qualitative HCV RNA testing will differentiate active from resolved infection.

Written Authorization

HCV Ab

Positive

Written Authorization Received. Authorization received from INNOCENTES SATOR 10-02-2008 Logged by Rhonda Shuffitt

01

LAB: 01 MB LabCorp Birmingham 1801 First Avenue South, Birmingham,

DIRECTOR: John Elgin N MD

35233-1935

Spec #: 274-766-2195-1 \*



LabCorp Birnungham

1801 First Avenue South, Birmingham, AL 35233-1935

Phone: 205-581-3500

SPECIMEN TYPE PRIMARY LAB REPORT STATUS
274-766-2195-0 S MB COMPLETE Page #: 1

ADDITIONAL INFORMATION

FASTING: N DOB: 9/17/1959

PATIENT NAME SEX AGE(YR./MOS.)
DEAN,FRED M 49 /

PT. ADD.:

 DATE OF COLLECTION TIME
 DATE RECEIVED
 DATE REPORTED
 TIME

 9/30/2008
 11:50
 9/30/2008
 10/01/2008
 17:05
 8937

CLINICAL INFORMATION
CD- 41295410023

PHYSICIAN ID. NPI PATIENT ID.
SATOR I 244104

ACCOUNT: Riverbend Maximum Security Institution

7475 Cockrill Bend Indr Rd

NASHVILLE TN 37209-0000

ACCOUNT NUMBER: 41839940

TEST RESULT LAB LIMITS CBC With Differential/Platelet 5.9 WBC x10E3/uL 4.0 - 10.501 4.42 RBC x10E6/uL 4.10 - 5.6001 12.0L Hemoglobin g/dL 12.5 - 17.001 Hematocrit 37.2 36.0 - 50.001 MCV 84 FL 80 - 98 01 27.2 27.0 - 34.0MCH pq 01 32.3 MCHC 32.0 - 36.001 g/dL 13.6 RDW 11.7 - 15.0 01 Platelets 222 140 415 01 x10E3/uL Neutrophils 31 L 40 - 74 01 Lymphs 60 H - 46 14 01 Monocytes 8 13 01 Eos - 7 0 1 01 Basos 0 0 = 3 01 Neutrophils (Absolute) 1.8 x10E3/uL 1.8 - 7.801 Lymphs (Absolute) 3.5 x10E3/uL 0.7 - 4.501 Monocytes (Absolute) 0.5 x10E3/uL 0.1 - 1.001 Eos (Absolute) 0.1 0.0 - 0.4x10E3/uL 01 Baso (Absolute) 0.0 x10E3/uL 0.0 - 0.201 Comp. Metabolic Panel (14) Glucose, Serum mg/dL 65 - 99 01 BUN 12 mg/dL 5 - 2601 Creatinine, Serum 1.11 mg/dL 0.76 - 1.2701 Glom Filt Rate, Est mL/min/1.73 60 - 137 If African-American >59 mL/min/1.73 60 - 137 Note: Persistent reduction for 3 months or more in an eGFR <60 mL/min/1.73 m2 defines CKD. Patients with eGFR values >/=60 mL/min/1.73 m2 may also have CKD if evidence of persistent proteinuria is present. Additional information may be found at www.kdogi.org. BUN/Creatinine Ratio 11 - 27 Sodium, Serum 138 135 - 145 mmol/L 01 Potassium, Serum 5.0 mmol/L 3.5 - 5.201 Chloride, Serum 101 mmol/L 97 - 10801 Carbon Dioxide, Total 22 mmol/L 20 - 32 01 - 10.6 Calcium, Serum mq/dL 8.5 01 Protein, Total, Serum 7.9 g/dL 6.0 - 8.5 Albumin, Serum 4.6 g/dL 3.5 - 5.5Globulin, Total 1.5 q/dL Seq #: 893 Pat Name: DEAN, FRED Pat ID: 244104 Spec #: 274-766-2195-0

Results are Flagged in Accordance with Age Dependent Reference Ranges



TYPE

S

SPECIMEN

274-766-2195-0

LabCorp Birntingham

1801 First Avenue South, Birmingham, AL 35233-1935

PRIMARY LAB | REPORT STATUS COMPLETE Page#: 2 Phone: 205-581-3500

#### ADDITIONAL INFORMATION

FASTING: N. DOB: 9/17/1959

PATIENT NAME SEX AGE(YR./MOS.) 49 / DEAN, FRED M

PT. ADD.:

DATE RECEIVED DATE REPORTED DATE OF COLLECTION TIME TIME 9/30/2008 11:50 9/30/2008 10/01/2008 17:05 8937

**CLINICAL INFORMATION** CD-41295410023 PHYSICIAN ID. NPI PATIENT ID. SATOR I 244104

ACCOUNT: Riverbend Maximum Security Institution

7475 Cockrill Bend Indr Rd

NASHVILLE TN 37209-0000 ACCOUNT NUMBER: 41839940

TEST	RESI	JLT	LIMITS	LAB
A/G Ratio	1.4		1.1 - 2.5	
Bilirubin, Total	0.4	mg/dL	0.1 - 1.2	01
Alkaline Phosphatase, S	115	TU/L	25 - 150	01
AST (SGOT)	(39)	IU/L	0 - 40	01
ALT (SGPT)	45	IU/L	0 - 55	01
Iron and TIBC				
Iron Bind.Cap.(TIBC)	322	ug/dL	250 - 450	
UIBC	222	ug/dL	150 - 375	01
Iron, Şerum	100	ug/dL	40 - 155	01
Iron Saturation	31	9 E	15 - 55	
Thyroid Panel With TSH				
TSH	1.637	uIU/mL	0.450 - 4.500	01
Thyroxine (T4)	9.7	ug/dL	4.5 - 12.0	01
T3 Uptake	22 L	*	24 - 39	01
Free Thyroxine Index	2.1		1.2 - 4.9	
Rheumatoid Arthritis Factor			1911年第二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	
RA Latex Turbid.	<7.0	IU/mL	0.0 - 13.9	01
Uric Acid, Serum	6.5	mg/dL	2.4 - 8.2	01
Sedimentation Rate-Westergren	4	-mm/hr	0   - 15	01
HBsAg Screen	Confirm.	ndicated	Negative	01
HBsAg Confirmation	Positive	11		01

LAB: 01 MB LabCorp Birmingham

1801 First Avenue South, Birmingham, AL 35233-1935

DIRECTOR: John Elgin N MD Innocentes Safor MP

Pat Name: DEAN, FRED

Pat ID: 244104

Spec #: 274-766-2195-0

Seq #: 8937

# Hepatitis C Workup and Treatment Guidelines Tennessee Region

### **Hepatitis C Immunoassay Positive**

#### **Initial Assumptions:**

- No unstable medical and mental health conditions;
- No contraindication to interferon (Ribavirin if can't use monotherapy in genotype 2,3)
- Genotypes 1, 4, and 6 treatment would proceed if earliest release date is >15 months;
- Genotypes 2, 3 treatment would proceed if earliest release date is > 9 months;
- Patient has not refused

#### Physical Exam

Determine if any or all of the following are present and what severity: Encephalopathy; Hepatomegaly; and Asterixis. Also evidence of CHF or volume overload.

#### Laboratory studies to order

- Order HCV Genotype
- Order hemoglobin; MCV; Absolute Neutrophil Count (ANC); Platelet count; Alkaline
   Phosphatase; Total Bilirubin; ALT; AST; Albumin; and PT / INR
- Order HCV RNA (Viral Load) at ≤ 2 months before treatment initiation.

### Determine the stage of fibrosis using the SAFE Algorithm

- Primarily in genotype 1
- Calculate the APRI (AST/LPT Ratio Index) then use the SAFE Algorithm
- Caveat Genotype 2, 3 Routinely no fibrosis evaluation is needed so no need to use the SAFE Algorithm <u>UNLESS</u> a high suspicion of cirrhosis. Then the algorithm is used.

**Determine the Severity of Cirrhosis** (well compensated; significant functional compromise, or decompensated). Therefore, use the CTP below only if cirrhosis is present.

Use the CTP (Child-Turcotte-Pugh) Score

#### Decide on Therapy (Dual vs Triple)

#### Triple Therapy

 Only Genotype 1, Stage 4/Cirrhosis patients AND declining platelet count and/or evidence of liver dysfunction. Everyone else would be dual therapy.

#### **Dual Therapy**

- All Genotypes 2,3 (but can prioritize by treating only those with cirrhosis)
- Prioritize Genotypes 1, 4, and 6 (stages 2 4)

#### **Exclusion criteria**

■ Platelet count <70,000	<ul> <li>Unstable medical conditions (e.g. uncontrolled diabetes; COPD,</li> </ul>
ANC <1500	and CHF)
CTP Score ≥ 7	Unstable mental health conditions (e.g. depression)
Contraindication to	Ribavirin is contraindicated in patients with CrCl <50; pregnancy,
interferon	and history of pancreatitis
<ul> <li>Solid organ transplantation</li> </ul>	<ul> <li>Hemoglobinopathies except sickle cell trait</li> </ul>

#### Hepatoma Screening Hep C positive patients with cirrhosis

Ultrasound every 6 months in diabetics and non-diabetics